90 146

Cited 0 times in

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus

 Jong Suk Park  ;  Min Ho Cho  ;  Hyun Chul Lee  ;  Kyung Rae Kim  ;  Bong Soo Cha  ;  ChulWoo Ahn  ;  Jeong Seon Yoo  ;  Ji Sun Nam 
 European Journal of Endocrinology, Vol.164(1) : 69-74, 2011 
Journal Title
 European Journal of Endocrinology 
Issue Date
OBJECTIVE: Osteoprotegerin (OPG) acts as an important regulatory molecule in atherosclerosis. Recent studies report that thiazolidinediones could affect OPG expression. We investigated the relationship between OPG and inflammatory cytokines and the effects of pioglitazone (a PPARγ (PPARG) agonist) versus metformin on serum OPG levels in type 2 diabetic patients. DESIGN AND METHODS: Sixty-seven type 2 diabetic patients were included in this study. They were assigned to pioglitazone (15 mg/day, n=34) or metformin (1000 mg/day, n=33) during 24 weeks. Various anthropometric and metabolic parameters, OPG, interleukin 6 (IL6), C-reactive protein (CRP), adiponectin, and homeostasis model assessment of insulin resistance (HOMA-IR), were measured at baseline and at 6 months of treatment. RESULTS: Serum OPG levels correlated significantly with fasting plasma glucose (FPG), HbAlc, HOMA-IR, IL6, and CRP, and inversely correlated with adiponectin after adjusting for age (P<0.05). Multiple regression analysis showed that FPG, HbAlc, and adioponectin were independently correlated with OPG level. After 6 months of treatment, the reduction in FPG and HbAlc levels was similar between the two groups. Pioglitazone treatment significantly increased body mass index (P<0.05) and waist circumference (P<0.05) and decreased triglycerides (P<0.05) and HOMA-IR (P<0.01). The adiponectin concentration was increased (P<0.05), and OPG and CRP levels were decreased in the pioglitazone group (P<0.05), but were unchanged in the metformin group. The changes in serum OPG in the pioglitazone group showed significant correlation with changes in FPG, HbAlc, and adiponectin. CONCLUSIONS: In type 2 diabetic patients, pioglitazone decreases OPG levels, and this decrease in OPG levels might be associated with the increase in adiponectin.
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
김경래(Kim, Kyung Rae) ; 남지선(Nam, Ji Sun) ; 박종숙(Park, Jong Suk) ; 안철우(Ahn, Chul Woo) ; 유정선(Yoo, Jeong Seon) ; 이현철(Lee, Hyun Chul) ; 조민호(Cho, Min Ho) ; 차봉수(Cha, Bong Soo)
사서에게 알리기
Files in This Item:
T201101181.pdf Download
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.